Exploring the Single-Cell Dynamics of FOXM1 Under Cell Cycle Perturbations

Abstract

The cell cycle is crucial for maintaining normal cellular functions and preventing replication errors. FOXM1, a key transcription factor, plays a pivotal role in regulating cell cycle progression and is implicated in various physiological and pathological processes, including cancers like liver, prostate, breast, lung and colon cancer. Despite previous research, our understanding of FOXM1 dynamics under different cell cycle perturbations and its connection to heterogeneous cell fate decisions remains limited. In this study, we investigated FOXM1 behaviour in individual cells exposed to various perturbagens. We found that different drugs induce diverse responses due to heterogeneous FOXM1 dynamics at the single-cell level. Single-cell analysis identified six distinct cellular phenotypes: on-time cytokinesis, cytokinesis delay, cell cycle delay, G1 arrest, G2 arrest and cell death, observed across different drug types and doses. Specifically, treatments with PLK1, CDK1, CDK1/2 and Aurora kinase inhibitors revealed varied FOXM1 dynamics leading to heterogeneous cellular outcomes. Our findings affirm that the dynamics of FOXM1 are essential in shaping cellular outcomes, influencing the signals that dictate responses to various stimuli. Our results gave insights into how FOXM1 dynamics contribute to cell cycle fate decisions, especially under different cell cycle perturbations.

Keywords

biosensor / cell cycle / drug screening / FOXM1 / single cell dynamics

References

[1] J. C. Saldivar, S. Hamperl, M. J. Bocek, et al., “An Intrinsic S/G(2) Checkpoint Enforced by ATR,” Science 361, no. 6404 (2018): 806-810.

[2] D. Kalathil, S. John, and A. S. Nair, “FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis,” Frontiers in Oncology 10 (2020): 626836.

[3] Z. Wang, S. Banerjee, D. Kong, Y. Li, and F. H. Sarkar, “Down-Regulation of Forkhead Box M1 Transcription Factor Leads to the Inhibition of Invasion and Angiogenesis of Pancreatic Cancer Cells,” Cancer Research 67, no. 17 (2007): 8293-8300.

[4] M. Alvarez- Fernandez and R. H. Medema, “Novel Functions of FoxM1: From Molecular Mechanisms to Cancer Therapy,” Frontiers in Oncology 3 (2013): 30.

[5] Y. Tan, P. Raychaudhuri, and R. H. Costa, “Chk2 Mediates Stabilization of the FoxM1 Transcription Factor to Stimulate Expression of DNA Repair Genes,” Molecular and Cellular Biology 27, no. 3 (2007): 1007-1016.

[6] A. M. Barsotti and C. Prives, “Pro-Proliferative FoxM1 Is a Target of p53-Mediated Repression,” Oncogene 28, no. 48 (2009): 4295-4305.

[7] F. D. Naso, D. Boi, C. Ascanelli, et al., “Nuclear Localisation of Aurora-A: Its Regulation and Significance for Aurora-A Functions in Cancer,” Oncogene 40, no. 23 (2021): 3917-3928.

[8] F. Yu, H. He, L. J. Nastoupil, et al., “Targetable Vulnerability of Deregulated FOXM1/PLK1 Signaling Axis in Diffuse Large B Cell Lymphoma,” American Journal of Cancer Research 12, no. 10 (2022): 4666-4679.

[9] I. C. Wang, Y. J. Chen, D. Hughes, et al., “Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase,” Molecular and Cellular Biology 25, no. 24 (2005): 10875-10894.

[10] I. Wierstra, “FOXM1 (Forkhead Box M1) in Tumorigenesis: Overexpression in Human Cancer, Implication in Tumorigenesis, Oncogenic Functions, Tumor-Suppressive Properties, and Target of Anticancer Therapy,” Advances in Cancer Research 119 (2013): 191-419.

[11] C. Gu, X. Jing, C. Holman, et al., “Upregulation of FOXM1 Leads to Diminished Drug Sensitivity in Myeloma,” BMC Cancer 18, no. 1 (2018): 1152.

[12] H. J. Park, G. Gusarova, Z. Wang, et al., “Deregulation of FoxM1b Leads to Tumour Metastasis,” EMBO Molecular Medicine 3, no. 1 (2011): 21-34.

[13] J. C. Macedo, S. Vaz, B. Bakker, et al., “FoxM1 Repression During Human Aging Leads to Mitotic Decline and Aneuploidy-Driven Full Senescence,” Nature Communications 9, no. 1 (2018): 2834.

[14] A. L. G. S. K. Radhakrishnan, “Lost in Transcription: p21 Repression, Mechanisms, and Consequences,” Cancer Research 65, no. 10 (2005): 3980-3985.

[15] B. Dai, R. O. Pieper, D. Li, et al., “FoxM1B Regulates NEDD4-1 Expression, Leading to Cellular Transformation and Full Malignant Phenotype in Immortalized Human Astrocytes,” Cancer Research 70, no. 7 (2010): 2951-2961.

[16] J. Millour, D. Constantinidou, A. V. Stavropoulou, et al., “FOXM1 Is a Transcriptional Target of ERalpha and Has a Critical Role in Breast Cancer Endocrine Sensitivity and Resistance,” Oncogene 29, no. 20 (2010): 2983-2995.

[17] S. L. Spencer, S. D. Cappell, F. C. Tsai, K. W. Overton, C. L. Wang, and T. Meyer, “The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit,” Cell 155, no. 2 (2013): 369-383.

[18] J. Debnath, S. K. Muthuswamy, and J. S. Brugge, “Morphogenesis and Oncogenesis of MCF-10A Mammary Epithelial Acini Grown in Three-Dimensional Basement Membrane Cultures,” Methods 30, no. 3 (2003): 256-268.

[19] W. Korver, J. Roose, K. Heinen, et al., “The Human TRIDENT/HFH-11/FKHL16 Gene: Structure, Localization, and Promoter Characterization,” Genomics 46 (1997): 435-442.

[20] J. R. Lin, M. Fallahi-Sichani, J. Y. Chen, and P. K. Sorger, “Cyclic Immunofluorescence (CycIF), A Highly Multiplexed Method for Single-Cell Imaging,” Current Protocols in Chemical Biology 8, no. 4 (2016): 251-264.

[21] H. M. Taieb, L. Bertinetti, T. Robinson, and A. Cipitria, “FUCCItrack: An All-In-One Software for Single Cell Tracking and Cell Cycle Analysis,” PLoS One 17, no. 7 (2022): e0268297.

[22] L. M. Zheng Fu, J. Huang, W. Wang, et al., “Plk1-Dependent Phosphorylation of FoxM1 Regulates a Transcriptional Programme Required for Mitotic Progression,” Nature Cell Biology 10, no. 9 (2009): 1076-1082.

[23] J. Pines and T. Hunter, “Isolation of a Human Cyclin cDNA: Evidence for Cyclin mRNA and Protein Regulation in the Cell Cycle and for Interaction With p34cdc2,” Cell 58, no. 5 (1989): 833-846.

[24] R. Hamanaka, M. R. Smith, P. M. O'Connor, et al., “Polo-Like Kinase Is a Cell Cycle-Regulated Kinase Activated During Mitosis,” Journal of Biological Chemistry 270, no. 36 (1995): 21086-21091.

[25] H. J. Park, R. H. Costa, L. F. Lau, A. L. Tyner, and P. Raychaudhuri, “Anaphase-Promoting Complex/Cyclosome-CDH1-Mediated Proteolysis of the Forkhead Box M1 Transcription Factor Is Critical for Regulated Entry Into S Phase,” Molecular and Cellular Biology 28, no. 17 (2008): 5162-5171.

[26] H. J. Choi, M. Fukui, and B. T. Zhu, “Role of Cyclin B1/Cdc2 Up-Regulation in the Development of Mitotic Prometaphase Arrest in Human Breast Cancer Cells Treated With Nocodazole,” PLoS One 6, no. 8 (2011): e24312.

[27] B. R. Pennycook and A. R. Barr, “Palbociclib-Mediated Cell Cycle Arrest Can Occur in the Absence of the CDK Inhibitors p21 and p27,” Open Biology 11, no. 11 (2021): 210125.

[28] L. Fischer, A. Schnaiter, B. Freysoldt, et al., “The Novel CDK4/6-Inhibitor Abemaciclib Induces Early G1-Arrest in MCL Cell Lines, Sensitizes Cells to Cytarabine Treatment and Is Additive With Ibrutinib,” Blood 126, no. 23 (2015): 5124, https://doi.org/10.1182/blood.V126.23.5124.5124.

[29] X. Liu, Y. Shi, K. W. Woods, et al., “Akt Inhibitor a-443654 Interferes With Mitotic Progression by Regulating Aurora A Kinase Expression,” Neoplasia 10, no. 8 (2008): 828-837.

[30] T. W. C. Leung, S. S. W. Lin, A. C. C. Tsang, et al., “Over-Expression of FoxM1 Stimulates Cyclin B1 Expression,” FEBS Letters 507, no. 1 (2001): 59-66.

[31] M. Halasi and A. L. Gartel, “A Novel Mode of FoxM1 Regulation: Positive Auto-Regulatory Loop,” Cell Cycle 8, no. 12 (2009): 1966-1967.

[32] J. Zeng, L. Wang, Q. Li, et al., “FoxM1 Is Up-Regulated in Gastric Cancer and Its Inhibition Leads to Cellular Senescence, Partially Dependent on p27 kip1,” Journal of Pathology 218, no. 4 (2009): 419-427.

[33] M. S. Chesnokov, S. Borhani, M. Halasi, Z. Arbieva, I. Khan, and A. L. Gartel, “FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML,” Frontiers in Oncology 11 (2021): 696532.

[34] V. Chand, X. Liao, G. Guzman, E. Benevolenskaya, and P. Raychaudhuri, “Hepatocellular Carcinoma Evades RB1-Induced Senescence by Activating the FOXM1-FOXO1 Axis,” Oncogene 41, no. 30 (2022): 3778-3790.

[35] J. Carter, W. Z. Barger, J. Hillman, et al., “Genetic Determinants of FOXM1 Overexpression in Epithelial Ovarian Cancer and Functional Contribution to Cell Cycle Progression,” Oncotarget 6 (2015): 27613-27627.

[36] Y. Tan, Q. Wang, Y. Xie, et al., “Identification of FOXM1 as a Specific Marker for Triple-Negative Breast Cancer,” International Journal of Oncology 54, no. 1 (2019): 87-97.

[37] N. Yang, C. Wang, J. Wang, et al., “Aurora Kinase A Stabilizes FOXM1 to Enhance Paclitaxel Resistance in Triple-Negative Breast Cancer,” Journal of Cellular and Molecular Medicine 23, no. 9 (2019): 6442-6453.

[38] L. Anders, N. Ke, P. Hydbring, et al., “A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells,” Cancer Cell 20, no. 5 (2011): 620-634.

[39] M. L. Major, R. Lepe, and R. H. Costa, “Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators,” Molecular and Cellular Biology 24, no. 7 (2004): 2649-2661.

[40] N. Yang, C. Wang, Z. Wang, et al., “FOXM1 Recruits Nuclear Aurora Kinase A to Participate in a Positive Feedback Loop Essential for the Self-Renewal of Breast Cancer Stem Cells,” Oncogene 36, no. 24 (2017): 3428-3440.

[41] E. Montaudon, J. Nikitorowicz-Buniak, L. Sourd, et al., “PLK1 Inhibition Exhibits Strong Anti-Tumoral Activity in CCND1-Driven Breast Cancer Metastases With Acquired Palbociclib Resistance,” Nature Communications 11, no. 1 (2020): 4053.

[42] M. Hafner, C. E. Mills, K. Subramanian, et al., “Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity,” Cell Chemical Biology 26, no. 8 (2019): 1067-1080 e8.

[43] S. Gookin, M. Min, H. Phadke, et al., “A Map of Protein Dynamics During Cell-Cycle Progression and Cell-Cycle Exit,” PLoS Biology 15, no. 9 (2017): e2003268.

[44] M. Min, Y. Rong, C. Tian, and S. L. Spencer, “Temporal Integration of Mitogen History in Mother Cells Controls Proliferation of Daughter Cells,” Science 368, no. 6496 (2020): 1261-1265.

[45] C. Yang, C. Tian, T. E. Hoffman, N. K. Jacobsen, and S. L. Spencer, “Melanoma Subpopulations That Rapidly Escape MAPK Pathway Inhibition Incur DNA Damage and Rely on Stress Signalling,” Nature Communications 12, no. 1 (2021): 1747.

[46] M. Min and S. L. Spencer, “Spontaneously Slow-Cycling Subpopulations of Human Cells Originate From Activation of Stress-Response Pathways,” PLoS Biology 17, no. 3 (2019): e3000178.

[47] S. Sampattavanich, B. Steiert, B. A. Kramer, B. M. Gyori, J. G. Albeck, and P. K. Sorger, “Encoding Growth Factor Identity in the Temporal Dynamics of FOXO3 Under the Combinatorial Control of ERK and AKT Kinases,” Cell Systems 6, no. 6 (2018): 664-678 e9.

[48] A. E. Granada, A. Jimenez, J. Stewart-Ornstein, et al., “The Effects of Proliferation Status and Cell Cycle Phase on the Responses of Single Cells to Chemotherapy,” Molecular Biology of the Cell 31, no. 8 (2020): 845-857.

[49] E. Batchelor, A. Loewer, and G. Lahav, “The Ups and Downs of p53: Understanding Protein Dynamics in Single Cells,” Nature Reviews. Cancer 9, no. 5 (2009): 371-377.

[50] J. E. Purvis, K. W. Karhohs, C. Mock, E. Batchelor, A. Loewer, and G. Lahav, “p53 Dynamics Control Cell Fate,” Science 336, no. 6087 (2012): 1440-1444.

[51] J. E. Purvis and G. Lahav, “Encoding and Decoding Cellular Information Through Signaling Dynamics,” Cell 152, no. 5 (2013): 945-956.

[52] J. Stewart-Ornstein, H. W. J. Cheng, and G. Lahav, “Conservation and Divergence of p53 Oscillation Dynamics Across Species,” Cell Systems 5, no. 4 (2017): 410-417 e4.

[53] N. Kosaisawe, B. Sparta, M. Pargett, C. K. Teragawa, and J. G. Albeck, “Transient Phases of OXPHOS Inhibitor Resistance Reveal Underlying Metabolic Heterogeneity in Single Cells,” Cell Metabolism 33, no. 3 (2021): 649-665 e8.

[54] S. J. Altschuler and L. F. Wu, “Cellular Heterogeneity: Do Differences Make a Difference?,” Cell 141, no. 4 (2010): 559-563.

[55] K. Phongkitkarun, P. Chusorn, M. Kamkaew, E. W. F. Lam, C. Promptmas, and S. Sampattavanich, “Chemically Tunable FOXM1-D Sensor Revealed FOXM1 Direct Influence on Cell Cycle,”2023.

[56] A. Raj and A. van Oudenaarden, “Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences,” Cell 135, no. 2 (2008): 216-226.

[57] S. Xie, Y. Cai, D. Chen, et al., “Single-Cell Transcriptome Analysis Reveals Heterogeneity and Convergence of the Tumor Microenvironment in Colorectal Cancer,” Frontiers in Immunology 13 (2022): 1003419.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.